Pancreatic Masses
Conditions
Brief summary
The goal of this observational study is to learn if a strategy can be developed for differentiating autoimmune pancreatitis (AIP) and primary pancreatic lymphoma (PPL) from pancreatic ductal adenocarcinoma (PDAC) in patients presenting with pancreatic masses. The main question it aims to answer is: What features, in the perspectives of clinical manifestation, laboratory tests, and imaging, can differentiate different kinds of pancreatic masses (AIP, PPL and PDAC)? Participants will not be given any interventions since this is a retrospective observational study.
Interventions
None listed
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Inpatients presenting with pancreatic masses and eventually diagnosed with PPL, AIP, or PDAC (confirmed by pathologic results).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic nomogram | From date of admission into the hospital to the establishment of diagnosis, assessed up to 100 months |
Secondary
| Measure | Time frame |
|---|---|
| serum level of LDH | From date of admission into the hospital to the establishment of diagnosis, assessed up to 100 months |
| serum level of IgG4 | From date of admission into the hospital to the establishment of diagnosis, assessed up to 100 months |
| largest diameter of pancreatic masses | From date of admission into the hospital to the establishment of diagnosis, assessed up to 100 months |
| dilation of pancreatic duct | From date of admission into the hospital to the establishment of diagnosis, assessed up to 100 months |
Outcome results
None listed